These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2791499)

  • 21. Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens.
    Stratton CW; Weeks LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):29S-34S. PubMed ID: 2791495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lomefloxacin activity against 2,813 clinical isolates: a collaborative study at three medical centers in Brazil.
    Magalhaes M; Trabulsi LR; Montelli AC
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):35S-39S. PubMed ID: 2791496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of sparfloxacin compared with those of five other quinolones.
    Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
    Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.
    Jones RN; Aldridge KE; Barry AL; Fuchs PC; Gerlach EH; Pfaller MA; Washington JA
    Diagn Microbiol Infect Dis; 1988 Aug; 10(4):221-40. PubMed ID: 3072151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of lomefloxacin.
    Piddock LJ; Hall MC; Wise R
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1088-93. PubMed ID: 2168142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of lomefloxacin and other antimicrobials against 597 microorganisms causing bacteremia.
    Weinstein MP
    Diagn Microbiol Infect Dis; 1988 Dec; 11(4):195-200. PubMed ID: 3071448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):164-8. PubMed ID: 2498101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa.
    Aldridge KE; Henderberg A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):1S-6S. PubMed ID: 2507219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
    Edwards R; Kanematsu M; Greenwood D
    J Antimicrob Chemother; 1988 Dec; 22(6):885-90. PubMed ID: 3243736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
    Chin NX; Novelli A; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):656-62. PubMed ID: 3164987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial effects of lomefloxacin in vitro.
    Chambers ST; Peddie BA; Robson RA; Begg EJ; Boswell DR
    J Antimicrob Chemother; 1991 Apr; 27(4):481-9. PubMed ID: 1856127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility pattern of bacterial isolates to lomefloxacin.
    Lalitha MK; Nisha AK; Bhattacharya SS; Ramamoorthy U; Lal HM
    Indian J Med Res; 1990 May; 91():182-4. PubMed ID: 2397938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone.
    Visser MR; Rozenberg-Arska M; Beumer H; Hoepelman IM; Verhoef J
    Antimicrob Agents Chemother; 1991 May; 35(5):858-68. PubMed ID: 1854167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of lomefloxacin as compared with ciprofloxacin.
    Inderlied CB; Lancero MG; Bermudez LM; Young LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):17S-20S. PubMed ID: 2791493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lomefloxacin (SC-47111 or NY-198). Comparative antimicrobial activity against 2002 clinical isolates from hospitals in Mexico City.
    Durazo F; Resano F; Gonzalez MA
    Diagn Microbiol Infect Dis; 1990; 13(1):71-5. PubMed ID: 2331854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils.
    Pruul H; McDonald PJ
    J Antimicrob Chemother; 1990 Jan; 25(1):91-101. PubMed ID: 2108116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.